Information on the target
Astorg, a pan-European private equity firm specializing in healthcare and life sciences, has successfully finalized the acquisition of the microbiology division of Thermo Fisher Scientific. This entity will operate as an independent company, led by Dirk Bontridder as CEO, and is set to launch under a new brand by the end of 2026. The transaction, announced in late April 2026 and completed in August, is valued at approximately $1.075 billion, comprising both cash and a seller's credit of $50 million. The divested business, previously part of Thermo Fisher's Specialty Diagnostics segment, generated $645 million in revenue in 2025.
The acquired division provides consumables and diagnostic equipment used in microbiological testing across clinical, food safety, and pharmaceutical markets. Key offerings include antimicrobial susceptibility testing and culture media solutions, marketed under the Remel and Oxoid brands. The division serves over 15,000 clients in approximately 100 countries and employs around 2,400 staff across 13 production and R&D sites globally.
Industry overview in the target’s specific country
The Bio Diagnostics & Testing industry in the target country is experiencing significant growth, driven by increasing demand for advanced diagnostic solutions and a heightened focus on public health. The sector is characterized by a robust regulatory framework that ensures high standards of quality and safety in diagnostic products. This environment fosters innovation and encourages investment in research and development, leading to the introduction of cutting-edge technologies and methodologies in microbiological testing.
Moreover, the ongoing global health challenges have underscored the importance of reliable diagnostic tools, propelling the Bio Diagnostics & Testing industry to the forefront of healthcare priorities. The integration of artificial intelligence and machine learning into diagnostic processes is further enhancing the accuracy and efficiency of testing, thereby expanding the market's potential. This trend is particularly evident in the clinical diagnostics segment, where rapid testing solutions are becoming increasingly essential.
In addition, the food safety and pharmaceutical sectors are also contributing to the industry's growth, as regulatory bodies impose stricter quality control measures. The demand for microbiological testing in these areas is expected to rise, driven by consumer awareness and the need for compliance with safety standards. As a result, companies operating in the Bio Diagnostics & Testing industry are well-positioned to capitalize on these trends, making it an attractive sector for investment.
Overall, the Bio Diagnostics & Testing industry in the target country is poised for continued expansion, supported by technological advancements, regulatory developments, and an increasing emphasis…